At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
Obicetrapibdrug
Likely dose
Obicetrapib 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Proof-of-Concept, Open-Label Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Obicetrapib in Patients With Early Alzheimer's Disease (Hetero/Homozygote APOE4 Carriers)
In Brief
A Phase 2 clinical trial evaluating Obicetrapib for Early Alzheimer's Disease. Completed, enrolled 13 participants across 1 site.
Detailed Summary
A Phase 2a study in men and women with early Alzheimer's disease to evaluate the pharmacodynamics, pharmacokinetics and safety of obicetrapib therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEarly Alzheimer's Disease
CountriesNetherlands
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedDec 2021
Enrollment StartJan 2022
Primary CompletionMay 2023
Study CompletionJun 2023
TodayJul 2026
First PostedDec 17, 2021
Enrollment StartJan 12, 2022
Primary CompletionMay 9, 2023
Study CompletionJun 1, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.5 years ago
Interventions
Obicetrapibdrug
10mg obicetrapib